Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.41 |
| ▸ | MMP3 | P08254 | 8/20 | 0.41 |
| ▸ | MMP7 | P09237 | 7/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 6/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562691 | 0.85 | ACE (0.43) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL19003911 | 0.82 | KDM4E (0.42) | MMP2MMP3MMP7TSHR | |
| SCHEMBL5564199 | 0.79 | KMT2A (0.40) | MMP2MMP3MMP7MMP1 | |
| SCHEMBL890102 | 0.77 | ALDH1A1 (0.35) | MMP2MMP3MMP7 | |
| SCHEMBL13154045 | 0.77 | CYP2C9 (0.39) | MMP2MMP3MMP7TSHR | |
| SCHEMBL13160460 | 0.77 | ALDH1A1 (0.35) | MMP2MMP3MMP7 | |
| SCHEMBL24473443 | 0.75 | — | — | |
| SCHEMBL12588684 | 0.75 | — | — | |
| SCHEMBL14520476 | 0.75 | MME (0.41) | MMP8ACE | |
| SCHEMBL15779623 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572203-B1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | EP | disclosed |
| US-7109225-B2 | Antidiabetic agents; hypotensive agents; anticholesterol agents; antilipemic agents; antiinflammatory agents; antiproliferative agents | HOFMANN-LA ROCHE INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040157898-A1 | Novel substituted oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157898-A1 | Novel substituted oxazole derivatives | OXA1L, SLC5A1, GPR119 | MMP2 3413/4885MMP3 3064/4885MMP7 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.